Zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients (Pts) with claudin-18.2+(CLDN18.2+) / HER2-locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study Meeting Abstract


Authors: Lordick, F.; Shitara, K.; Bang, Y. J.; Enzinger, P.; Ilson, D.; Shah, M. A.; Van Cutsem, E.; Xu, R. H.; Aprile, G.; Xu, J.; Chao, J.; Pazo-Cid, R.; Kang, Y. K.; Yang, J.; Moran, D.; Bhattacharya, P.; Arozullah, A.; Park, J. W.; Ajani, J.
Abstract Title: Zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients (Pts) with claudin-18.2+(CLDN18.2+) / HER2-locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study
Meeting Title: Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie (2023)
Journal Title: Oncology Research and Treatment
Volume: 46
Issue: Suppl. 5
Meeting Dates: 2023 Oct 13-16
Meeting Location: Hamburg, Germany
ISSN: 2296-5270
Publisher: S. Karger AG  
Date Published: 2023-10-01
Start Page: 115
End Page: 116
Language: English
ACCESSION: WOS:001091456900244
PROVIDER: wos
PUBMED: 37788643
DOI: 10.1159/000533576
Notes: Meeting Abstract: V841 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. David H Ilson
    433 Ilson